MCID: EST001
MIFTS: 51

Estrogen-Receptor Positive Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Estrogen-Receptor Positive Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Positive Breast Cancer:

Name: Estrogen-Receptor Positive Breast Cancer 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0060075

Summaries for Estrogen-Receptor Positive Breast Cancer

MalaCards based summary : Estrogen-Receptor Positive Breast Cancer is related to estrogen-receptor negative breast cancer and fallopian tube carcinoma. An important gene associated with Estrogen-Receptor Positive Breast Cancer is HSPB8 (Heat Shock Protein Family B (Small) Member 8), and among its related pathways/superpathways are Signaling by GPCR and GPCR Pathway. The drugs Anastrozole and Exemestane have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Estrogen-Receptor Positive Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 177)
# Related Disease Score Top Affiliating Genes
1 estrogen-receptor negative breast cancer 30.8 ERBB2 ESR1 FOXA1 PGR
2 fallopian tube carcinoma 30.6 ERBB2 ESR1 PGR TP53
3 small cell cancer of the lung 29.5 AKT1 EGFR PIK3CA TP53
4 breast cancer 26.7 AKT1 CCND1 CYP19A1 EGFR ERBB2 ESR1
5 scirrhous adenocarcinoma 10.9 ERBB2 PGR
6 breast apocrine carcinoma 10.9 ERBB2 PGR
7 breast papillomatosis 10.9 CCND1 ERBB2
8 vulvar syringoma 10.9 ESR1 PGR
9 lung leiomyoma 10.9 ESR1 PGR
10 endometrial clear cell adenocarcinoma 10.9 ESR1 TP53
11 endometrium carcinoma in situ 10.9 PGR TP53
12 vulvar benign neoplasm 10.9 ESR1 PGR
13 trigonitis 10.9 ESR1 PGR
14 vulvar leiomyoma 10.8 ESR1 PGR
15 breast mucoepidermoid carcinoma 10.8 ERBB2 PGR
16 gallbladder squamous cell carcinoma 10.8 ERBB2 TP53
17 gastric papillary adenocarcinoma 10.8 ERBB2 TP53
18 breast metaplastic carcinoma 10.8 ERBB2 PGR
19 glassy cell carcinoma of the cervix 10.8 ERBB2 ESR1 PGR
20 adult hepatocellular carcinoma 10.7 PIK3CA TP53
21 breast medullary carcinoma 10.7 ERBB2 ESR1 PGR
22 predominantly cortical thymoma 10.7 ESR1 PGR
23 vestibular gland benign neoplasm 10.7 ESR1 PGR TP53
24 bartholin's gland adenoma 10.7 ESR1 PGR TP53
25 apocrine adenocarcinoma 10.7 ERBB2 ESR1 PGR
26 comedo carcinoma 10.7 ERBB2 ESR1
27 non-proliferative fibrocystic change of the breast 10.7 CCND1 ERBB2 TP53
28 endometrial squamous cell carcinoma 10.7 CCND1 ESR1 PGR
29 oral leukoplakia 10.7 CCND1 ERBB2 TP53
30 cervical carcinosarcoma 10.7 ESR1 PGR TP53
31 glycogen-rich clear cell breast carcinoma 10.7 ESR1 PGR TP53
32 bilateral breast cancer 10.7 ERBB2 ESR1 PGR
33 breast papillary carcinoma 10.7 ERBB2 ESR1 PGR
34 uterine body mixed cancer 10.7 ERBB2 PGR TP53
35 adenosarcoma 10.7 ESR1 PGR TP53
36 dermatosis papulosa nigra 10.7 MTOR PIK3CA
37 malignant spiradenoma 10.7 PIK3CA TP53
38 uterine corpus serous adenocarcinoma 10.7 ERBB2 TP53
39 breast intraductal proliferative lesion 10.7 EGFR ERBB2
40 esophagus adenocarcinoma 10.7 ERBB2 PIK3CA TP53
41 papillary adenocarcinoma 10.7 ERBB2 PGR TP53
42 bladder squamous cell carcinoma 10.6 ERBB2 PIK3CA TP53
43 brain ependymoma 10.6 EGFR TP53
44 progesterone resistance 10.6 ESR1 PGR
45 bent bone dysplasia syndrome 10.6 ERBB2 FGFR2
46 gender identity disorder 10.6 CYP19A1 ESR1 PGR
47 estrogen excess 10.5 CYP19A1 ESR1 PGR
48 mammographic density 10.5 CYP19A1 ESR1 PGR
49 hemimegalencephaly 10.5 CCND1 MTOR PIK3CA
50 endometriosis of ovary 10.5 CYP19A1 ESR1 PGR

Graphical network of the top 20 diseases related to Estrogen-Receptor Positive Breast Cancer:



Diseases related to Estrogen-Receptor Positive Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Positive Breast Cancer

GenomeRNAi Phenotypes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

26 (show top 50) (show all 61)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.64 EGFR MTOR PIK3CA
2 Decreased viability GR00107-A-1 10.64 HSPB8
3 Decreased viability GR00221-A-1 10.64 HSPB8 EGFR ESR1 AKT1 MTOR PIK3CA
4 Decreased viability GR00221-A-2 10.64 ESR1 AKT1 PIK3CA
5 Decreased viability GR00221-A-3 10.64 ERBB2 AKT1
6 Decreased viability GR00221-A-4 10.64 HSPB8 EGFR ERBB2 ESR1 AKT1 MTOR
7 Decreased viability GR00301-A 10.64 HSPB8
8 Decreased viability GR00342-S-1 10.64 MTOR
9 Decreased viability GR00342-S-2 10.64 MTOR
10 Decreased viability GR00402-S-2 10.64 ERBB2 ESR1 HSPB8 EGFR AKT1 MTOR
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 10.28 FOXA1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.28 CCND1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.28 MTOR
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.28 CCND1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 10.28 CCND1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.28 PIK3CA FOXA1 CCND1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.28 RAB31
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.28 FOXA1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.28 PIK3CA RAB31 FOXA1 CCND1 MTOR
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.28 PIK3CA MTOR
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.28 CCND1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.24 MTOR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.24 MTOR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.24 FOXA1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.24 PIK3CA FOXA1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.24 CCND1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.24 FOXA1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.24 NCOA3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.24 FOXA1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.24 NCOA3
31 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.24 CCND1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.24 PIK3CA
33 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.24 PIK3CA FOXA1 CCND1 AKT1 MTOR
34 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.24 CCND1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.24 PIK3CA
36 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.24 PIK3CA FOXA1 CCND1 AKT1 NCOA3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.24 FOXA1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.24 PIK3CA
39 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.24 CCND1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.24 FOXA1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.24 CCND1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.24 CCND1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.24 FOXA1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.24 CCND1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.24 CCND1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.24 PIK3CA FOXA1 AKT1 MTOR
47 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.24 PIK3CA
48 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.24 AKT1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.24 FOXA1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.24 AKT1

MGI Mouse Phenotypes related to Estrogen-Receptor Positive Breast Cancer:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 PGR NCOA3 PIK3CA STAT5B TP53 ERBB2
2 endocrine/exocrine gland MP:0005379 10.41 NCOA3 PIK3CA PGR STAT5B TP53 ESR1
3 homeostasis/metabolism MP:0005376 10.41 PGR NCOA3 PIK3CA STAT5B TP53 ERBB2
4 behavior/neurological MP:0005386 10.38 PIK3CA MTOR PGR NCOA3 TP53 STAT5B
5 cardiovascular system MP:0005385 10.38 PGR PIK3CA TP53 ERBB2 EGFR ESR1
6 growth/size/body region MP:0005378 10.37 NCOA3 PIK3CA TP53 STAT5B ESR1 ERBB2
7 immune system MP:0005387 10.37 PGR NCOA3 PIK3CA STAT5B TP53 EGFR
8 integument MP:0010771 10.32 PGR NCOA3 PIK3CA STAT5B TP53 EGFR
9 mortality/aging MP:0010768 10.32 PGR NCOA3 PIK3CA TP53 STAT5B ESR1
10 adipose tissue MP:0005375 10.31 NCOA3 PIK3CA STAT5B TP53 EGFR ESR1
11 hematopoietic system MP:0005397 10.29 MTOR PGR NCOA3 TP53 STAT5B EGFR
12 embryo MP:0005380 10.27 PGR NCOA3 PIK3CA TP53 ERBB2 EGFR
13 digestive/alimentary MP:0005381 10.24 NCOA3 TP53 ERBB2 EGFR ESR1 CCND1
14 muscle MP:0005369 10.23 PGR NCOA3 PIK3CA TP53 ERBB2 EGFR
15 neoplasm MP:0002006 10.17 PGR NCOA3 PIK3CA TP53 EGFR ESR1
16 liver/biliary system MP:0005370 10.1 NCOA3 TP53 STAT5B EGFR AKT1 CYP19A1
17 nervous system MP:0003631 10.1 MTOR PIK3CA TP53 ERBB2 EGFR CCND1
18 normal MP:0002873 10.1 PGR NCOA3 STAT5B TP53 ERBB2 EGFR
19 reproductive system MP:0005389 9.93 PGR NCOA3 PIK3CA STAT5B TP53 ERBB2
20 no phenotypic analysis MP:0003012 9.91 PIK3CA MTOR PGR TP53 EGFR FGFR2
21 renal/urinary system MP:0005367 9.86 MTOR NCOA3 TP53 STAT5B EGFR CYP19A1
22 respiratory system MP:0005388 9.61 TP53 ERBB2 EGFR ESR1 CCND1 AKT1
23 skeleton MP:0005390 9.4 PGR NCOA3 PIK3CA TP53 ERBB2 EGFR

Drugs & Therapeutics for Estrogen-Receptor Positive Breast Cancer

Drugs for Estrogen-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 207)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120511-73-1 2187
2
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 107868-30-4 60198
3
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129453-61-8 104741 17756771
4
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 112809-51-5 3902
5
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
6
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
9 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
10 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
11 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Antifungal Agents Phase 4,Phase 3,Phase 2
24 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
25
Bevacizumab Approved, Investigational Phase 3,Phase 2,Not Applicable 216974-75-3
26
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Not Applicable 50-18-0, 6055-19-2 2907
27
Docetaxel Approved, Investigational Phase 3,Not Applicable 114977-28-5 148124
28
Epirubicin Approved Phase 3 56420-45-2 41867
29
Fluorouracil Approved Phase 3 51-21-8 3385
30
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 57-83-0 5994
31
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
32
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
33 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 979-32-8
34
Polyestradiol phosphate Approved Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
35
Palbociclib Approved, Investigational Phase 3,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
36
Goserelin Approved Phase 3,Phase 2 65807-02-5 47725 5311128
37
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
38
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
39
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
40
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
41
Pertuzumab Approved Phase 3 145040-37-5, 380610-27-5 2540
42
Leuprolide Approved, Investigational Phase 3 53714-56-0 3911 657181
43
Metformin Approved Phase 3,Phase 2 657-24-9 14219 4091
44
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
45
Norepinephrine Approved Phase 3 51-41-2 439260
46
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
47
Methyltestosterone Approved Phase 3 58-18-4 6010
48
Testosterone Approved, Investigational Phase 3 58-22-0 6013
49
Testosterone enanthate Approved Phase 3 315-37-7 9416
50
Testosterone undecanoate Approved, Investigational Phase 3 5949-44-0

Interventional clinical trials:

(show top 50) (show all 148)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Completed NCT01231659 Phase 4 Everolimus + Letrozole
2 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
3 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
4 Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer Unknown status NCT01104571 Phase 3 lapatinib ditosylate
5 Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00893061 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
6 Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
7 Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery Completed NCT00963729 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil;letrozole
8 S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Completed NCT01385137 Phase 3
9 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
10 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
11 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
12 Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer Recruiting NCT02947685 Phase 3 palbociclib;trastuzumab;pertuzumab;letrozole;Anastrozole;Exemestane;Fulvestrant
13 A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations (STEP) Recruiting NCT03137368 Phase 3 Exemestane Tablets;Tamoxifen
14 Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial Recruiting NCT03011684 Phase 3 Tamoxifen;Letrozole
15 S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Recruiting NCT01674140 Phase 3 anastrozole;everolimus;exemestane;goserelin acetate;letrozole;leuprolide acetate;tamoxifen citrate
16 Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Active, not recruiting NCT00265759 Phase 3 anastrozole;exemestane;letrozole
17 Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
18 Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066690 Phase 3 Exemestane;Tamoxifen;Triptorelin
19 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066703 Phase 3 exemestane;tamoxifen;triptorelin
20 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Active, not recruiting NCT01598298 Phase 3 duloxetine hydrochloride
21 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
22 Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment Active, not recruiting NCT01573442 Phase 3 testosterone
23 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
24 A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Active, not recruiting NCT01101438 Phase 3 metformin hydrochloride
25 Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Active, not recruiting NCT00433589 Phase 3 anthracycline-based;docetaxel and capecitabine
26 Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery Active, not recruiting NCT00541086 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
27 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
28 S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Suspended NCT02137837 Phase 3 Fulvestrant;Anastrozole;Everolimus;Placebo - Anastrozole;Placebo - Everolimus
29 Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer Terminated NCT00684216 Phase 2, Phase 3 capecitabine;hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
30 Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients Terminated NCT01809171 Phase 2, Phase 3 Vitamin D3;Placebo
31 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Unknown status NCT01124695 Phase 2 tamoxifen citrate
32 Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer Unknown status NCT00871858 Phase 2 anastrozole;fulvestrant
33 Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer Unknown status NCT00687648 Phase 2 anastrozole;cyclophosphamide;exemestane;letrozole;methotrexate;prednisolone
34 PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Unknown status NCT01037790 Phase 2 PD-0332991
35 Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00931450 Phase 1, Phase 2 exemestane;sunitinib malate
36 Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer Completed NCT00093002 Phase 2 Fulvestrant
37 A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) Completed NCT01234857 Phase 2 ridaforolimus + dalotuzumab;exemestane;ridaforolimus;dalotuzumab
38 Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer Completed NCT00767520 Phase 2 Exemestane + Dasatinib;Exemestane + Placebo
39 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
40 Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women Completed NCT00107016 Phase 2 RAD001, Letrozole 2.5mg;Letrozole 2.5mg
41 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ Completed NCT01439711 Phase 2 letrozole
42 AKT Inhibitor in Oestrogen Positive Breast Cancer Completed NCT02077569 Phase 2 AZD5363
43 Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers Completed NCT00467493 Phase 2 Anastrozole
44 Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer Completed NCT00676663 Phase 2 entinostat;exemestane
45 Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer Completed NCT00057941 Phase 2 anastrozole;gefitinib;fulvestrant
46 Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer Completed NCT00082810 Phase 2 fulvestrant;tipifarnib
47 Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery Completed NCT00407888 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel albumin-stabilized nanoparticle formulation
48 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed NCT01194440 Phase 2 letrozole;zoledronic acid
49 Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
50 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan

Search NIH Clinical Center for Estrogen-Receptor Positive Breast Cancer

Genetic Tests for Estrogen-Receptor Positive Breast Cancer

Anatomical Context for Estrogen-Receptor Positive Breast Cancer

MalaCards organs/tissues related to Estrogen-Receptor Positive Breast Cancer:

41
Breast, Bone, Lymph Node, Testes, Brain, Skin, Kidney

Publications for Estrogen-Receptor Positive Breast Cancer

Articles related to Estrogen-Receptor Positive Breast Cancer:

(show top 50) (show all 395)
# Title Authors Year
1
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. ( 29905023 )
2018
2
Alcohol, Smoking, and Risk of Her2-Overexpressing and Triple-Negative Breast Cancer Relative to Estrogen Receptor-Positive Breast Cancer. ( 29708591 )
2018
3
Interaction between dietary acrylamide intake and genetic variants for estrogen receptor-positive breast cancer risk. ( 29445914 )
2018
4
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. ( 29436393 )
2018
5
Expression signature of ten genes predicts the survival of patients with estrogen receptor positive-breast cancer that were treated with tamoxifen. ( 29928444 )
2018
6
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. ( 29562737 )
2018
7
miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer. ( 29247596 )
2018
8
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. ( 29202611 )
2018
9
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. ( 29450494 )
2018
10
Omega-3 Polyunsaturated Fatty Acids Time-Dependently Reduce Cell Viability and Oncogenic MicroRNA-21 Expression in Estrogen Receptor-Positive Breast Cancer Cells (MCF-7). ( 29342901 )
2018
11
Effect of pyruvate kinase M2-regulating aerobic glycolysis on chemotherapy resistance of estrogen receptor-positive breast cancer. ( 29782350 )
2018
12
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer. ( 29128895 )
2018
13
Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer. ( 29127189 )
2018
14
A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. ( 29733541 )
2018
15
Wnt5a-induced cell migration is associated with the aggressiveness of estrogen receptor-positive breast cancer. ( 29765514 )
2018
16
A New Class of Agents for Estrogen-Receptor-Positive Breast Cancer. ( 29439601 )
2018
17
Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer. ( 29363090 )
2018
18
Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel. ( 29373839 )
2018
19
Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients. ( 29895278 )
2018
20
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer. ( 29483206 )
2018
21
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer. ( 29867779 )
2018
22
Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. ( 29719270 )
2018
23
Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer. ( 29626519 )
2018
24
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. ( 29352052 )
2018
25
18F-Fluoroestradiol PET/CT Correctly Diagnosed 18F-FDG-Avid Inflammatory Lymph Nodes in a Patient With Estrogen Receptor-Positive Breast Cancer. ( 29485433 )
2018
26
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. ( 29676944 )
2018
27
MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer. ( 28597750 )
2017
28
Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen. ( 28852212 )
2017
29
miR-125a-3p inhibits ERI+ transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer. ( 28939591 )
2017
30
Genetic and environmental factors and serum hormones, and risk of estrogen receptor-positive breast cancer in pre- and postmenopausal Japanese women. ( 29029469 )
2017
31
HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells. ( 29326587 )
2017
32
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. ( 29078133 )
2017
33
Wnt7a Deficiency Could Predict Worse Disease-Free and Overall Survival in Estrogen Receptor-Positive Breast Cancer. ( 29285041 )
2017
34
Leptin is overexpressed in the tumor microenvironment of obese patients with estrogen receptor positive breast cancer. ( 28565832 )
2017
35
Anti-cancer stem cell activity of a hedgehog inhibitor GANT61 in estrogen receptor-positive breast cancer cells. ( 28211214 )
2017
36
Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells. ( 28415819 )
2017
37
Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer. ( 28581884 )
2017
38
21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. ( 28702894 )
2017
39
Targeting cell necroptosis and apoptosis induced by Shikonin via receptor interacting protein kinases in estrogen receptor positive breast cancer cell line, MCF-7. ( 28933271 )
2017
40
Identify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapy. ( 27866092 )
2017
41
Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers. ( 28929082 )
2017
42
Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones. ( 28791495 )
2017
43
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. ( 28270497 )
2017
44
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. ( 28324268 )
2017
45
PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression. ( 28347547 )
2017
46
Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. ( 28147342 )
2017
47
Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy. ( 29147583 )
2017
48
High tumor-infiltrating FoxP3(+) T cells predict poor survival in estrogen receptor-positive breast cancer: A meta-analysis. ( 28214052 )
2017
49
Activation of hypoxia-inducible factor-1I+ by prolonged inA vivo hyperinsulinemia treatment potentiates cancerous progression in estrogen receptor-positive breast cancer cells. ( 28351619 )
2017
50
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. ( 29325860 )
2017

Variations for Estrogen-Receptor Positive Breast Cancer

Expression for Estrogen-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Positive Breast Cancer.

Pathways for Estrogen-Receptor Positive Breast Cancer

Pathways related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 115)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.26 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
2
Show member pathways
13.8 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
3
Show member pathways
13.57 AKT1 EGFR ERBB2 FGFR2 MTOR STAT5B
4
Show member pathways
13.51 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
5
Show member pathways
13.49 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
6
Show member pathways
13.44 AKT1 CCND1 EGFR ERBB2 FGFR2 PIK3CA
7
Show member pathways
13.21 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
8
Show member pathways
13.12 AKT1 EGFR ESR1 NCOA3 PGR PIK3CA
9
Show member pathways
13.05 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
10
Show member pathways
12.96 AKT1 EGFR ERBB2 MTOR PIK3CA
11
Show member pathways
12.96 AKT1 CCND1 MTOR PIK3CA STAT5B
12
Show member pathways
12.96 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
13
Show member pathways
12.95 AKT1 CCND1 EGFR ERBB2 PIK3CA
14
Show member pathways
12.88 AKT1 CCND1 EGFR ERBB2 MTOR STAT5B
15
Show member pathways
12.88 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
16
Show member pathways
12.86 AKT1 CCND1 PIK3CA STAT5B TP53
17 12.84 AKT1 EGFR ERBB2 FGFR2 TP53
18
Show member pathways
12.81 AKT1 ERBB2 ESR1 MTOR PIK3CA TP53
19
Show member pathways
12.81 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
20
Show member pathways
12.77 AKT1 CCND1 EGFR MTOR PIK3CA STAT5B
21
Show member pathways
12.73 AKT1 CCND1 EGFR MTOR PIK3CA STAT5B
22
Show member pathways
12.69 AKT1 EGFR ERBB2 PIK3CA STAT5B TP53
23
Show member pathways
12.67 AKT1 CCND1 MTOR PIK3CA STAT5B TP53
24 12.62 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
25 12.61 CCND1 EGFR ERBB2 MTOR PIK3CA TP53
26
Show member pathways
12.61 AKT1 CCND1 EGFR ERBB2 MTOR PIK3CA
27
Show member pathways
12.56 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
28
Show member pathways
12.54 AKT1 CCND1 MTOR PIK3CA TP53
29 12.53 AKT1 CCND1 PIK3CA STAT5B TP53
30
Show member pathways
12.53 AKT1 CCND1 ERBB2 ESR1 MTOR PIK3CA
31
Show member pathways
12.51 AKT1 CCND1 EGFR ERBB2 MTOR PIK3CA
32
Show member pathways
12.49 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
33
Show member pathways
12.48 AKT1 FGFR2 MTOR PIK3CA
34
Show member pathways
12.47 AKT1 EGFR MTOR PIK3CA
35
Show member pathways
12.39 AKT1 EGFR ERBB2 PIK3CA
36 12.37 CCND1 PIK3CA STAT5B TP53
37
Show member pathways
12.37 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
38
Show member pathways
12.36 AKT1 CCND1 EGFR ERBB2 ESR1 NCOA3
39
Show member pathways
12.31 CCND1 ESR1 NCOA3 PGR
40
Show member pathways
12.3 AKT1 MTOR STAT5B TP53
41 12.28 AKT1 CCND1 EGFR TP53
42 12.28 AKT1 CCND1 MTOR PIK3CA TP53
43
Show member pathways
12.27 AKT1 MTOR PIK3CA TP53
44 12.27 AKT1 EGFR ERBB2 MTOR NCOA3 STAT5B
45 12.27 AKT1 CCND1 EGFR ERBB2 ESR1 MTOR
46
Show member pathways
12.26 AKT1 FGFR2 MTOR PIK3CA
47
Show member pathways
12.23 AKT1 EGFR ERBB2 PIK3CA
48
Show member pathways
12.23 AKT1 MTOR PIK3CA TP53
49
Show member pathways
12.19 AKT1 CCND1 EGFR PIK3CA
50
Show member pathways
12.19 AKT1 CCND1 EGFR ERBB2 MTOR PIK3CA

GO Terms for Estrogen-Receptor Positive Breast Cancer

Cellular components related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.93 AKT1 CCND1 ERBB2 ESR1 HSPB8 MTOR
2 protein-containing complex GO:0032991 9.43 AKT1 EGFR ESR1 MTOR NCOA3 TP53
3 nucleoplasm GO:0005654 9.36 AKT1 CCND1 ESR1 FGFR2 FOXA1 HSPB8
4 phosphatidylinositol 3-kinase complex GO:0005942 9.26 MTOR PIK3CA

Biological processes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 AKT1 EGFR ESR1 FGFR2 FOXA1 NCOA3
2 peptidyl-tyrosine phosphorylation GO:0018108 9.91 EGFR ERBB2 FGFR2 STAT5B
3 protein autophosphorylation GO:0046777 9.89 AKT1 EGFR ERBB2 FGFR2 MTOR
4 positive regulation of protein phosphorylation GO:0001934 9.88 AKT1 CCND1 EGFR ERBB2 MTOR
5 lung development GO:0030324 9.86 EGFR FGFR2 FOXA1
6 liver development GO:0001889 9.85 CCND1 EGFR PIK3CA
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.85 AKT1 EGFR PIK3CA
8 positive regulation of cell growth GO:0030307 9.84 AKT1 EGFR ERBB2
9 wound healing GO:0042060 9.84 EGFR ERBB2 FGFR2 MTOR
10 positive regulation of kinase activity GO:0033674 9.83 EGFR ERBB2 FGFR2
11 positive regulation of epithelial cell proliferation GO:0050679 9.83 EGFR ERBB2 FGFR2
12 epidermal growth factor receptor signaling pathway GO:0007173 9.81 AKT1 EGFR PIK3CA
13 ERBB2 signaling pathway GO:0038128 9.78 EGFR ERBB2 PIK3CA
14 cellular response to estradiol stimulus GO:0071392 9.77 EGFR ESR1 NCOA3
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.76 AKT1 EGFR FGFR2 MTOR
16 phosphatidylinositol 3-kinase signaling GO:0014065 9.74 AKT1 ERBB2 PIK3CA
17 regulation of ERK1 and ERK2 cascade GO:0070372 9.73 EGFR ERBB2 FGFR2
18 cellular response to growth factor stimulus GO:0071363 9.73 AKT1 EGFR ERBB2 STAT5B
19 regulation of multicellular organism growth GO:0040014 9.72 FGFR2 PIK3CA STAT5B
20 negative regulation of ERBB signaling pathway GO:1901185 9.69 EGFR ERBB2
21 negative regulation of macroautophagy GO:0016242 9.69 AKT1 MTOR PIK3CA
22 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.68 ESR1 TP53
23 positive regulation of transcription by RNA polymerase III GO:0045945 9.67 ERBB2 MTOR
24 cellular response to epidermal growth factor stimulus GO:0071364 9.67 AKT1 EGFR ERBB2 STAT5B
25 mitotic G1 DNA damage checkpoint GO:0031571 9.66 CCND1 TP53
26 negative regulation of cell size GO:0045792 9.66 AKT1 MTOR
27 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.65 AKT1 EGFR
28 phosphatidylinositol phosphorylation GO:0046854 9.65 EGFR ERBB2 ESR1 FGFR2 PIK3CA
29 regulation of branching involved in prostate gland morphogenesis GO:0060687 9.64 ESR1 FGFR2
30 regulation of glycogen biosynthetic process GO:0005979 9.64 AKT1 MTOR
31 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis GO:0060527 9.63 ESR1 FGFR2
32 prostate epithelial cord elongation GO:0060523 9.58 ESR1 FGFR2
33 anoikis GO:0043276 9.58 AKT1 MTOR PIK3CA
34 response to estradiol GO:0032355 9.55 CCND1 EGFR ESR1 FOXA1 STAT5B
35 response to UV-A GO:0070141 9.13 AKT1 CCND1 EGFR
36 positive regulation of protein kinase B signaling GO:0051897 9.1 EGFR ERBB2 ESR1 FGFR2 MTOR PIK3CA
37 phosphorylation GO:0016310 10.09 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
38 positive regulation of cell proliferation GO:0008284 10.07 AKT1 CCND1 EGFR FGFR2 STAT5B
39 protein phosphorylation GO:0006468 10.07 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
40 negative regulation of apoptotic process GO:0043066 10.05 AKT1 EGFR ERBB2 FGFR2 STAT5B TP53
41 positive regulation of gene expression GO:0010628 10.02 AKT1 ERBB2 MTOR NCOA3 TP53
42 cytokine-mediated signaling pathway GO:0019221 10 AKT1 CCND1 PIK3CA STAT5B TP53

Molecular functions related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.97 AKT1 EGFR ERBB2 ESR1 HSPB8 MTOR
2 protein kinase binding GO:0019901 9.88 AKT1 CCND1 EGFR ESR1 MTOR TP53
3 kinase activity GO:0016301 9.87 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
4 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.86 ESR1 FOXA1 PGR STAT5B
5 nucleotide binding GO:0000166 9.85 AKT1 EGFR ERBB2 FGFR2 MTOR
6 protein tyrosine kinase activity GO:0004713 9.73 EGFR ERBB2 FGFR2 STAT5B
7 enzyme binding GO:0019899 9.73 AKT1 CCND1 EGFR ESR1 PGR TP53
8 MAP kinase kinase kinase activity GO:0004709 9.72 EGFR ERBB2 FGFR2
9 protein phosphatase binding GO:0019903 9.7 EGFR ERBB2 TP53
10 protein kinase activity GO:0004672 9.7 AKT1 CCND1 EGFR ERBB2 FGFR2 HSPB8
11 mitogen-activated protein kinase kinase binding GO:0031434 9.69 EGFR ERBB2 FGFR2
12 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.65 EGFR ERBB2 FGFR2
13 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.54 EGFR ERBB2
14 nitric-oxide synthase regulator activity GO:0030235 9.13 AKT1 EGFR ESR1
15 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.02 EGFR ERBB2 ESR1 FGFR2 PIK3CA
16 ATP binding GO:0005524 10.11 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
17 transferase activity GO:0016740 10.1 AKT1 EGFR ERBB2 FGFR2 MTOR NCOA3

Sources for Estrogen-Receptor Positive Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....